Pharmacogenetics, Kinetics, and Dynamics for Personalized Medicine

Pharmacogenetics, Kinetics, and Dynamics for Personalized Medicine provides a resource to understand pharmacogenetics (the study of genetic factors that influence how a patient responds to a drug) in the context of pharmacokinetics (how the body handles a drug) and pharmacodynamics (how a drug affects the body). This resource describes and emphasizes the interface of pharmacogenetics, kinetics and dynamics related to optimal drug therapy as part of personalized medicine. Specific gene-drug interaction case examples show how an individual's genetics may dictate the need for an altered dose or in some cases alternative drug therapy. The Pharmacogenetics, Kinetics and Dynamics for Personalized Medicine book provides a thorough review of pharmacokinetics, pharmacodynamics, and pharmacogenetics. The book includes evaluations of individual drug-gene pairs with a review of the current data, guidelines, and labeling information. The chapters are structured around clinical cases with an introduction and a chapter summary. The chapters present self-assessment questions at the end. Even more uniquely, each copy of the book affords a code for access to the Navigate Companion website where there are crossword puzzles, interactive flashcards, an interactive glossary, matching exercises, and weblinks for additional areas of study to reinforce content.


Type Book
CME Available No
Topic
Cost 35.95-70.95
Note Textbook

Genomic Competencies

Experts from the disciplines listed below have tagged this resource as fulfulling genomic competencies.

Pharmacist

  • Pharmacogenetics/Pharmacogenomics
    • P1:   To demonstrate an understanding of how genetic variation in a large number of proteins, including drug transporters, drug metabolizing enzymes, direct protein targets of drugs, and other proteins (e.g. signal transduction proteins) influence pharmacokinetics and pharmacodynamics related to pharmacologic effect and drug response
    • P2:   To understand the influence (or lack thereof) of ethnicity in genetic polymorphisms and associations of polymorphisms with drug response
    • P3:   Recognize the availability of evidence based guidelines that synthesize information relevant to genomic/pharmacogenomic tests and selection of drug therapy (e.g. Clinical Pharmacogenomics Implementation Consortium)